New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
07:55 EDTCLVS, CLVSClovis Oncology to host conference call
Conference call to discuss CO-101 LEAP study results will be held on November 12 at 8:30 am. Webcast Link
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:15 EDTCLVSASCO / ASTRO / IASLC to hold symposium
Subscribe for More Information
October 23, 2014
16:54 EDTCLVSClovis announces first patient enrolled in lucitanib Phase 2 study
Clovis Oncology announced that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer, or NSCLC, has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the company’s oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta. The Phase 2 study will enroll FGFR1-amplified squamous NSCLC patients with advanced disease who have progressed on at least one prior line of therapy. The global study will assess objective response rate, progression-free survival, and duration of response, as well as the safety, tolerability, and pharmacokinetics of lucitanib.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use